Nature medicine
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.
Lotte L Hoeijmakers, Petros Dimitriadis, Steven C M A Wijnen, Irene L M Reijers, Marta Lopez-Yurda, Alexander M Menzies, Annegien Broeks, Sten Cornelissen, Alejandro Torres Acosta, Anja van der Wal, Robyn P M Saw, Judith M Versluis, Winan J van Houdt, Michel W Wouters, Jurriaan Romano
Published: 202610.1038/s41591-025-04158-9
Abstract
Neoadjuvant ipilimumab plus nivolumab has become standard therapy for stage III melanoma based on the NADINA trial, although long-term data are lacking. In the phase 2 PRADO cohort of OpACIN-neo, 99 patients with stage III macroscopic melanoma receiv…
Preview only. Read the full abstract at the source